1. Home
  2. ASLE vs TRDA Comparison

ASLE vs TRDA Comparison

Compare ASLE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$6.09

Market Cap

309.5M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.45

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASLE
TRDA
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.5M
274.5M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ASLE
TRDA
Price
$6.09
$7.45
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$7.00
$21.00
AVG Volume (30 Days)
464.5K
294.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
N/A
EPS
N/A
N/A
Revenue
$335,286,000.00
$25,421,000.00
Revenue This Year
$23.41
$39.97
Revenue Next Year
$6.80
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$4.93
52 Week High
$9.08
$16.45

Technical Indicators

Market Signals
Indicator
ASLE
TRDA
Relative Strength Index (RSI) 39.60 49.88
Support Level $6.08 $5.75
Resistance Level $6.75 $10.82
Average True Range (ATR) 0.29 0.51
MACD -0.00 0.16
Stochastic Oscillator 0.00 60.57

Price Performance

Historical Comparison
ASLE
TRDA

About ASLE AerSale Corporation

AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: